Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639251 | 0.81 | ADORA2A (0.37) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL9010833 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL5667619 | 0.78 | ADORA2A (0.43) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL612166 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL16513158 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL932299 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL7168415 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL94915 | 0.78 | ADORA2A (0.35) | NUDT1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL7072636 | 0.76 | AKT2 (0.42) | AKT2NUDT1ADORA3KITADORA2A | |
| Water SCHEMBL3986355 | 0.76 | ADORA2A (0.34) | NUDT1ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401683-A1 | DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2018-11-14 | — | — | EP | claimed |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc | 2023-08-31 | — | — | US | disclosed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4165185-A2 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc, New York, NY (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021252903-A2 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | GENETIC INTELLIGENCE, INC, NEW YORK, NY (US) | 2021-12-16 | — | — | WO | disclosed |
| US-10668027-B1 | Method of treating Acanthamoeba infection using allopurinol | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3401683-A1 | DIAGNOSING METABOLIC DISEASE BY THE USE OF A BIOMARKER | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2018-11-14 | — | — | EP | disclosed |
| WO-2016043661-A1 | MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-03-24 | — | — | WO | disclosed |
| US-7608600-B2 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7365057-B2 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7192936-B2 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-5698685-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5506337-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0502690-A2 | Cyclopropane derivative | Ajinomoto Co., Inc. (JP) | 1992-09-09 | — | — | EP | disclosed |
| EP-0391592-A1 | Process for the enzymatic synthesis of nucleosides | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | FNIP1, FN1, TNNC1 | AKT2 3399/4885NUDT1 3137/4885ADORA3 4455/4885 |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | TARDBP, FUS, RBM17 | AKT2 4102/4885NUDT1 2858/4885ADORA3 4554/4885 |
| US-10668027-B1 | Method of treating Acanthamoeba infection using allopurinol | XDH, DPM1, GUSB | AKT2 4190/4885NUDT1 67/4885ADORA3 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.